Gut bacteria test could revolutionize colon cancer screening
NCT ID NCT06588166
First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 3 times
Summary
This study aims to develop a new, non-invasive diagnostic tool for colorectal cancer by analyzing gut microbiome signatures in stool samples. Researchers will enroll 1006 participants aged 50-74 who have tested positive on the standard fecal immunochemical test (FIT). By combining clinical data with microbial analysis using machine learning, they hope to create a scoring system that more accurately identifies cancer and advanced adenomas, potentially reducing the number of unnecessary colonoscopies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Gut microbiome testing
- What this could lead to
- If successful, this could provide a more accurate, non-invasive screening test for colorectal cancer, potentially reducing unnecessary colonoscopies.
- What could go wrong
- This is an observational study, not a treatment trial. The tool is still being developed and validated, so it may not prove accurate enough for widespread use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED COLORECTAL ADENOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fondazione Policlinico Agostino Gemelli, IRCCS
RECRUITINGRoma, 00168, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?